![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, June 19, 2019 6:30:28 PM
There are two other big reasons why I see MultiTAA as being pretty good.
Pretty good? Way to draw the readers in.
With Marker's cell therapy not being genetically modified, that means no serious adverse events, no cytokine release syndrome, and a lower manufacturing cost is possible.
Lower manufacturing cost is possible? Yea, that's not a novel idea. We already know what it costs to manufacture. It's been mentioned multiple times. $8,000-$10,000 and that's for multiple treatments. If you are trying to compare costs with CAR-T then why not just provide the actual cost? I'm guessing the author could have done a little more research.
First evidence of data in a solid tumor for MultiTAA will be in pancreatic cancer. It is very risky, because pancreatic cancer is not easy to treat. That means if data is not impressive to investors or the street, the stock may trade much lower. It's possible that the stock could be cut by 50% or more.
50% drop OR MORE on sub-par data? Come on. The pancreatic trial was not on anyone's radar until the end of March this year. Hell, it was barely a focus of the company until December when they got their first readout. The analysts starting coverage have based their price targets solely on AML. PC would just add to the value. Upon the announcement that they would be releasing PC data there was no huge run up. The SP was fairly stable and range bound. Institutions are heavily invested at $4. Again, based on the AML data. Clearly the data is good or they wouldn't have been in a rush to present it. Plus the bar is very low for PC. 50% was clearly just a random number the author pulled out of thin air.
Because Marker's product has no toxicity, it holds the potential to be given as an adjuvant as well after cancer is in remission. What that means is that, even if patients go and get treated with other immunotherapies such as CAR-T and TCR, there is an ability for patients to also obtain MultiTAA as an adjuvant/maintenance treatment. That's because MultiTAA has no side effects and no toxicity, so it could become a maintenance therapy as well. That means MultiTAA doesn't hurt anyone, so it can be given after a patient receives another immunotherapy just because it only serves to help that patient stay in remission.
Uhhhhh....??? Did a 12 year old write this. How many words do you need to say that because there is no toxicity MultiTAA can be given as an adjuvant therapy.
Obviously there was good content in the article although if you've been following the company you already knew all of it. Did the author miss a few things? Yea. Could it have been written a little better? 100%. I think at this point most people know that reading seeking alpha articles doesn't constitute DD since they have pretty low standards about what gets published.
As always, do your own DD.
Friends don't let friends place market orders
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM